ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

TargetBeta

EZH2

enhancer of zeste 2 polycomb repressive complex 2 subunit · also EZH1, ENX-1, KMT6, KMT6A · Histone lysine methyltransferases

6 programs in company-led studies act on EZH2, from 6 companies: 3 in phase 3. Each with where its target was read from.

Programs

Furthest phase first. A target read by rule is marked rule (4 of them); the others are the company’s own words or a reading by Claude, each quoted on the program’s page.

ProgramCompanyActs asFurthest phaseStudiesAlso acts onRead from
zeprumetostatruleJiangsu HengRui Medicineinhibitorphase 3177 running–NCIt
mevrometostatPfizerinhibitorphase 374 running–the company's pipeline
TR115ruleTarapeutics Scienceinhibitorphase 333 running–the studies' text
tulmimetostatNovartisinhibitorphase 233 runningEZH1the company's pipeline
EZH1/2 Inhibitor HH2853ruleHaihe Biopharmainhibitorphase 222 runningEZH1NCIt
valemetostatruleDaiichi Sankyoinhibitorphase 111 runningEZH1NCIt

Also acted on by the same programs

Primary completions ahead

Each program’s next study to reach its primary completion, by the sponsor’s estimate.

What this can’t show

  • Only programs whose target has been read: most early programs are named only by a code and their companies do not say what they act on.
  • A target read by rule can be wrong; each program’s page quotes the words it was read from.
  • “Acts as” is read from the words its target was read from — agonist, antagonist, inhibitor, lowers it (an siRNA or antisense drug), degrader — and is a dash where they do not say, or say two things; an antibody that only “binds” says neither.
  • Programs in company-led studies on ClinicalTrials.gov with a study in the last two years; academic studies and other registries are not counted here.